Skip to content

THE TIMES USA

The News that Matters

Menu
  • ABOUT
  • CONTACT
  • LIFESTYLE
  • NATIONAL NEWS
  • BUSINESS
  • INTERNATIONAL NEWS
  • TECHNOLOGY
  • PRICE OF BUSINESS SHOW AUDIOS
Menu

CAR-T Cell Lukemia Treatment is Proving to be a Game Changer for Long Term Survival

Posted on February 7, 2022 by admin

The following, provided with permission and in its entirety, from the University of Pennsylvania.

In the summer of 2010, Bill Ludwig and Doug Olson were battling an insidious blood cancer called chronic lymphocytic leukemia (CLL). They’d both received numerous treatments, and as remaining options became scarce, they volunteered to become the first participants in a clinical trial of an experimental therapy underway at the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The treatment would eradicate their end-stage leukemia, generate headlines across the globe, and usher in a new era of highly personalized medicine. Called Chimeric Antigen Receptor (CAR) T cells, these genetically modified tumor-targeting cells are a living drug made for each patient out of their own cells. Today, an analysis of these two patients published in Nature from the Penn researchers and colleagues from Children’s Hospital of Philadelphia explains the longest persistence of CAR T cell therapy recorded to date against CLL, and shows that the CAR T cells remained detectable at least a decade after infusion, with sustained remission in both patients.

“This long-term remission is remarkable, and witnessing patients living cancer-free is a testament to the tremendous potency of this “living drug” that works effectively against cancer cells,” said first author J. Joseph Melenhorst, PhD, a research professor of Pathology and Laboratory Medicine at Penn. “Witnessing our patients respond well to this innovative cellular therapy makes all of our efforts so worthwhile. being able to give them more time to live and to spend it with loved ones.”

CLL, the first cancer in which CAR T cells were studied and used at Penn, is the most common type of leukemia in adults. While treatment of the disease has improved, it remains incurable with standard approaches. Eventually, patients can become resistant to most therapies, and many still die of their disease.

Olson was diagnosed with CLL in 1996 and Ludwig in 2000. By 2010, their cancers had mutated and no longer responded to standard therapy. But as CAR T cell patient pioneers, both achieved complete remission that year. Olson, a former scientist, has taken up distance running and completed six half marathons. He also fundraises for the Leukemia and Lymphoma Society and helps newly diagnosed patients. After his treatment, Ludwig, a retired corrections officer, traveled the country with his wife in a motor home and celebrated milestone events with his family, from holidays to the arrival of new grandchildren. In early 2021, he died due to COVID-19 complications.

While durable remissions have been demonstrated in relapsed, refractory B cell malignancies with CD19-specific CAR T cells, before now, little has been known about the long-term potential and stability of the infused cells. In their latest analysis, the researchers observed an evolution of the CAR T cells over time, with a highly activated CD4+ cell population emerging and becoming dominant in both patients. The data suggest two distinct phases of CAR T-cell therapy responses in these patients with the initial phase dominated by killer T cells, and long term remission controlled by CD4+ T cells. In the ensuing years, these CD4+ cells continued to demonstrate tumor-cell-killing characteristics and ongoing proliferation, which is a hallmark of CAR T cells’ efficacy against cancer: its intense ability to survive and thrive inside the body.

The CD4 protein is encoded by the CD4 gene. CD4+ T helper cells are white blood cells that are a vital part of the immune system. In one patient, CD4+ cells made up 97.5 percent of CAR T cells at year 1.4 and then over 99.6 percent from year 3.4 to the latest time point (9.3 years) after infusion. In the second patient, CD4+ cells made up 97.6 percent of CAR T cells 7.2 years after infusion. This surprising finding of CD4+ cell dominance led researchers to rethink the possibility that CD4+ T cells may be primarily responsible for distinguishing T-helper from T-cytotoxic cells.

“CAR T cell therapy has been extremely effective for specific leukemias and lymphomas, and we look forward to continuing our efforts in these cancers, while also looking at their impact on solid tumors with research in this area to see more development in the coming years,” said David L. Porter, MD, the Jodi Fisher Horowitz Professor in Leukemia Care Excellence and director of Cell Therapy and Transplantation at Penn. “We often say that we learn something from every patient we treat with these therapies, and Bill and Doug, in particular, have given us so many clues that keep us focused on the next generation of personalized therapies.”

“Penn has begun testing next-generation T cells in more blood cancers, including lymphomas, and against the challenging solid tumor cancers,” said senior author Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in Pathology and Laboratory Medicine at Penn and director of the Center for Cellular Immunotherapies and the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania.  “A considerable amount of deep learning goes into studies that will fine tune the way cancer patients are treated with CAR T cells, and we look forward to the next phase of research and enhancements, including how best to use this approach to target other cancers and diseases.”

Penn scientists led research, development and clinical trials of this pioneering CAR T therapy in collaboration with Novartis and Children’s Hospital of Philadelphia. In 2017, the experimental therapy Ludwig and Olson received, now known as Kymriah®, became the first CAR T cell approved by the U.S. Food and Drug Administration (FDA), for the treatment of pediatric and young adult patients with acute lymphoblastic leukemia (ALL). The therapy was also approved for certain types of lymphoma in 2018.

Along with Melenhorst, Porter and June, the other co-corresponding authors are Gregory M. Chen, PhD, Graduate Group in Genomics and Computational Biology at Penn; Meng Wang, MS, Department of Pathology and Laboratory Medicine; and Kai Tan, MD, professor in the department of Pediatrics at The Children’s Hospital of Philadelphia.

The work was supported by Novartis Institute for Biomedical Research, the National Institutes of Health (R01-CA-241762-01,CA233285); Canadian Institutes of Health Research Doctoral Foreign Study Award (433117); and the NIH Medical Scientist Training Program (T32 GM07170).

Editor’s Note: The University of Pennsylvania has licensed some technologies involved in these studies to Novartis. Some of the scientists involved in these trials are inventors of these technologies. As a result of the licensing relationship with Novartis, the University of Pennsylvania receives significant financial benefit, and some of these inventors have benefitted financially and/or may benefit financially in the future. 

You Might Also Like...

  • Women and Long Term Care

    INTERVIEW ON THE PRICE OF BUSINESS SHOW, MEDIA PARTNER OF THIS SITE. Recently Kevin Price,…

  • baby in a car seat with a binky in his mouth
    Best Car Seats for Babies

    Your child will use multiple styles of car seats throughout the early years of their…

  • man writing product recall on glass
    Car Brands With the Most Recalls

    Though we often expect new vehicles to be in perfect working order, reality has shown…

  • Cell phones: More Effective Communication

      It may seem like forever ago, but there was once a time where having…

  • Long Term Care Firm Helps Financial Advisors Help Their Clients

    FROM THE PRICE OF BUSINESS, Media Partner of This Website   Recently Kevin Price, Host of…

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

VIDEO: This Week’s Best of our Network

https://www.thetimesusa.com/wp-content/uploads/2022/05/May-16-2022-This-Week-at-Read-Instead.mp4

GDPR Compliance

USABR does not collect data on its visitors.  For more information visit: https://www.usabusinessradio.com/contact-us/

Contact

Contact articles@usabusinessradio.net for more information on articles on this site. BMuyco@usabusinessradio.net for all other information.

Recent Articles

  • 5 Things a Small Business Owner Should Know Before Scaling
  • Different Types of Legal Fees Charged by Lawyers
  • Netflix Refuses to Bow Down to Woke Culture from Employees
  • eBikes Provide an Alternative to High Gas Prices
  • 5 Critical Mistakes To Avoid When Installing A Water Heater For The First Time

The Secret to Making New Rich Books Work

The Secret to Making New Rich Books Work

Also in TTUSA

  • Virtual Slot Machines To Play Free – How to open a new account in an online casino
  • Australian Casino Real Money – Slot machine for private use
  • Atlantic City Casino Slot Machines | Terms of the casino and live casino welcome bonus
  • Free Slot Casino Play – Free new slots: all new slot machines
  • Online Casino Lost A Lot Of Money | Online slot machines: online sites to play

RSS The Daily Blaze

  • Have You Installed the Vingo App? Open a Free Account Today
  • Famed Defense Attorney Looks at the “State of Texas vs. Melissa”
  • Powerful Habits To Become A Better Version Of Yourself 
  • A Guide to Decorating Your Wedding Venue (4 Vital Things to Remember)
  • Cyber Attack and the End of Lincoln College

The Leader in Business News

The Leader in Business News

RSS USA Business Radio

  • US Stock Market Moving Rapidly to a Bear Market
  • Thought Leaders Find Book Publishing a Powerful Tool
  • Today’s Power Sustainability Services in the Data Center
  • Former White House Economist Warns “Bracket Creep” is Back and More
  • The US Appears Headed Towards a Bear Market

RSS USA Daily Times

  • Chris Miles’ New Commentary Feature on Price of Business Digital Network
  • 6 Ways You Can’t Hide Text in Files, Emails and Other Data From a Search Engine
  • What to Do When Your Health Insurance Won’t Cover a Treatment
  • Post Reporter on Disaster Relief Disparity in Texas
  • Attorney on the Recent Rise of Unions and How it is Different than in the Past

RSS USA Daily Chronicles.

  • Is Now a Good Time to Sell a Business?
  • The Impact of the Roe vs. Wade Overturning Might Have Could Surprise People
  • Barbara Comstock Assess the Political Primary Season
  • The Role of HR in Business Management
  • Empowering Employees of the Future for the New Work World

RSS Price of Business

  • Managing Compliance As You Scale: 6 Tips
  • Sen. Manchin Joins GOP in Blasting Biden’s Interior Secretary
  • Post Reporter Takes Closer Look at the Problems with Crypto
  • Famed Defense Attorney Looks at the “State of Texas vs. Melissa”
  • US Stock Market Moving Rapidly to a Bear Market

RSS US Daily Review

  • Sen. Manchin Joins GOP in Blasting Biden’s Interior Secretary
  • The Benefits of IT Staff Augmentation Services
  • Handgun vs. Pistol: What’s Best for Self-Defense?
  • The “Tax Cuts Causes Inflation Argument” is Old and Requires Examination
  • Question Raised on Joe DeMarco’s Contribution to Sharon Ashe-Nadrowski Campaign

PoB Digital Network

US Daily Review

USA Business Radio

USA Daily Chronicles

USA Daily Times

The Daily Blaze

The Times USA

Price of Business

© 2022 THE TIMES USA | Powered by Superbs Personal Blog theme